Dravya Discovery supports biotech and pharmaceutical companies with advanced preclinical in vitro models and translational research services focused on ophthalmic diseases, helping accelerate the development of innovative therapies for vision-threatening conditions.
Our team combines deep expertise in ocular biology, disease modelling, and translational research to deliver reliable preclinical data that supports early drug discovery and development programmes.
From target validation to functional bioassays, our services help partners generate high-quality data to support decision-making across early-stage ophthalmology drug development.
Visual acuity test sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Discuss how regular eye exams can detect vision problems early on and more
Dravya Discovery provides preclinical in vitro research services focused on ophthalmology drug discovery and early translational research. Our services include human cell-based disease models, assay development, target validation, mechanistic studies, and efficacy testing across a range of ocular indications.
We support research across multiple ophthalmic indications, including:
We can also develop custom disease models tailored to specific research questions.
We use human-relevant cell-based models to replicate key disease mechanisms in the eye. These may include:
These models help evaluate drug efficacy, mechanism of action, and safety signals early in the discovery process.
Yes. In addition to established assays, we frequently develop bespoke experimental models and assays designed around specific drug targets, pathways, or therapeutic mechanisms.
Our scientists work closely with clients to ensure the assay captures relevant disease biology and delivers actionable data.